Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BUN5
UPID:
CC28B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BUN5; A8K789; Q8TBV8
Background:
Coiled-coil domain-containing protein 28B plays a pivotal role in ciliogenesis, influencing cilia length through interaction with MAPKAP1/SIN1, independent of the mTORC2 complex. It also modulates mTORC2 assembly and function, potentially enhancing AKT1 phosphorylation, without affecting mTORC1 complex assembly and function.
Therapeutic significance:
Given its involvement in Bardet-Biedl syndrome, a condition marked by severe pigmentary retinopathy, obesity, and other systemic manifestations, understanding the role of Coiled-coil domain-containing protein 28B could open doors to potential therapeutic strategies.